Disease · MONDO_0016698
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Radiation (Group 2) vs Sub-Total Resection Any Histology or Location (STR) (Group 3): serious adverse events | 38 of 281 | 55 of 64 | 345 | NCT00027846 | Trial comparisons |
| Stratum A: Recurrent High Grade Glioma vs Stratum B: Recurrent Ependymoma: serious adverse events | 14 of 16 | 9 of 13 | 29 | NCT01462695 | Trial comparisons |
| Intermediate-Risk Group vs High-Risk Group: Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan | 1 of 1 | 20 of 27 | 28 | NCT00602667 | Trial comparisons |
| Intermediate-Risk Group vs High-Risk Group: Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan | 0 of 1 | 8 of 27 | 28 | NCT00602667 | Trial comparisons |
| Erlotinib vs Etoposide: serious adverse events | 6 of 13 | 5 of 12 | 25 | NCT01032070 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 3 of 3 | 1 of 1 | 4 | NCT03727841 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants That Are Progression-free at 6 Months Time Point After Initiation of Treatment | 1 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants That Have Progressive Disease After 6 Months | 1 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants With 12-month Progression-free Survival (PFS12) | 0 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants Assessed Using the Response Assessment in Neuro-oncology Criteria (RANO) for Complete Response (CR) + Partial Response (PR) | 0 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
| 1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: deaths from any cause | 0 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
| 1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: serious adverse events | 1 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016698/comparisons